Ibaraki, Japan

Yukiko Enya

USPTO Granted Patents = 4 


 

Average Co-Inventor Count = 4.4

ph-index = 1

Forward Citations = 34(Granted Patents)


Location History:

  • Tsukuba, JP (2023)
  • Ibaraki, JP (2018 - 2024)

Company Filing History:


Years Active: 2018-2024

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Innovations by Yukiko Enya

Introduction

Yukiko Enya is a prominent inventor based in Ibaraki, Japan. She has made significant contributions to the field of biotechnology, particularly in the development of antisense nucleic acids. With a total of four patents to her name, her work has the potential to impact genetic therapies and treatments for muscular dystrophies.

Latest Patents

Yukiko Enya's latest patents include groundbreaking inventions such as an oligomer that allows exon 45 skipping in the human dystrophin gene. Additionally, she has developed an antisense nucleic acid that induces skipping of exon 50, providing a drug that causes highly efficient skipping of this exon in the human dystrophin gene. These innovations represent significant advancements in the treatment of genetic disorders.

Career Highlights

Throughout her career, Yukiko has worked with notable organizations, including Nippon Shinyaku Company, Ltd. and the National Center of Neurology and Psychiatry. Her experience in these institutions has allowed her to collaborate with leading experts in her field and contribute to important research initiatives.

Collaborations

Yukiko has collaborated with esteemed colleagues such as Shin'ichi Takeda and Yoshitsugu Aoki. These partnerships have further enhanced her research and development efforts in the realm of genetic therapies.

Conclusion

Yukiko Enya's innovative work in antisense nucleic acids showcases her dedication to advancing biotechnology. Her contributions have the potential to transform the landscape of genetic treatments and improve the lives of many individuals affected by genetic disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…